148 related articles for article (PubMed ID: 10563513)
21. Midazolam and triazolam biotransformation in mouse and human liver microsomes: relative contribution of CYP3A and CYP2C isoforms.
Perloff MD; von Moltke LL; Court MH; Kotegawa T; Shader RI; Greenblatt DJ
J Pharmacol Exp Ther; 2000 Feb; 292(2):618-28. PubMed ID: 10640299
[TBL] [Abstract][Full Text] [Related]
22. Characterization of CYP3A isozymes involved in the metabolism of domperidone: role of cytochrome b5 and inhibition by ketoconazole.
Michaud V; Simard C; Turgeon J
Drug Metab Lett; 2010 Apr; 4(2):95-103. PubMed ID: 21281268
[TBL] [Abstract][Full Text] [Related]
23. The oxidative metabolism of metoprolol in human liver microsomes: inhibition by the selective serotonin reuptake inhibitors.
Belpaire FM; Wijnant P; Temmerman A; Rasmussen BB; Brøsen K
Eur J Clin Pharmacol; 1998 May; 54(3):261-4. PubMed ID: 9681670
[TBL] [Abstract][Full Text] [Related]
24. Relative roles of CYP2C19 and CYP3A4/5 in midazolam 1'-hydroxylation.
Emoto C; Iwasaki K
Xenobiotica; 2007 Jun; 37(6):592-603. PubMed ID: 17614006
[TBL] [Abstract][Full Text] [Related]
25. In vitro metabolism of midazolam, triazolam, nifedipine, and testosterone by human liver microsomes and recombinant cytochromes p450: role of cyp3a4 and cyp3a5.
Patki KC; Von Moltke LL; Greenblatt DJ
Drug Metab Dispos; 2003 Jul; 31(7):938-44. PubMed ID: 12814972
[TBL] [Abstract][Full Text] [Related]
26. In vitro metabolism of quinidine: the (3S)-3-hydroxylation of quinidine is a specific marker reaction for cytochrome P-4503A4 activity in human liver microsomes.
Nielsen TL; Rasmussen BB; Flinois JP; Beaune P; Brosen K
J Pharmacol Exp Ther; 1999 Apr; 289(1):31-7. PubMed ID: 10086984
[TBL] [Abstract][Full Text] [Related]
27. Role of CYP3A4 in human hepatic diltiazem N-demethylation: inhibition of CYP3A4 activity by oxidized diltiazem metabolites.
Sutton D; Butler AM; Nadin L; Murray M
J Pharmacol Exp Ther; 1997 Jul; 282(1):294-300. PubMed ID: 9223567
[TBL] [Abstract][Full Text] [Related]
28. The novel azole R126638 is a selective inhibitor of ergosterol synthesis in Candida albicans, Trichophyton spp., and Microsporum canis.
Vanden Bossche H; Ausma J; Bohets H; Vermuyten K; Willemsens G; Marichal P; Meerpoel L; Odds F; Borgers M
Antimicrob Agents Chemother; 2004 Sep; 48(9):3272-8. PubMed ID: 15328084
[TBL] [Abstract][Full Text] [Related]
29. In vitro forecasting of drugs which may interfere with the biotransformation of midazolam.
Gascon MP; Dayer P
Eur J Clin Pharmacol; 1991; 41(6):573-8. PubMed ID: 1815969
[TBL] [Abstract][Full Text] [Related]
30. Propofol decreases the clearance of midazolam by inhibiting CYP3A4: an in vivo and in vitro study.
Hamaoka N; Oda Y; Hase I; Mizutani K; Nakamoto T; Ishizaki T; Asada A
Clin Pharmacol Ther; 1999 Aug; 66(2):110-7. PubMed ID: 10460064
[TBL] [Abstract][Full Text] [Related]
31. Dynamically simulating the interaction of midazolam and the CYP3A4 inhibitor itraconazole using individual coupled whole-body physiologically-based pharmacokinetic (WB-PBPK) models.
Vossen M; Sevestre M; Niederalt C; Jang IJ; Willmann S; Edginton AN
Theor Biol Med Model; 2007 Mar; 4():13. PubMed ID: 17386084
[TBL] [Abstract][Full Text] [Related]
32. Differentiation of intestinal and hepatic cytochrome P450 3A activity with use of midazolam as an in vivo probe: effect of ketoconazole.
Tsunoda SM; Velez RL; von Moltke LL; Greenblatt DJ
Clin Pharmacol Ther; 1999 Nov; 66(5):461-71. PubMed ID: 10579473
[TBL] [Abstract][Full Text] [Related]
33. Role of itraconazole metabolites in CYP3A4 inhibition.
Isoherranen N; Kunze KL; Allen KE; Nelson WL; Thummel KE
Drug Metab Dispos; 2004 Oct; 32(10):1121-31. PubMed ID: 15242978
[TBL] [Abstract][Full Text] [Related]
34. Cytochrome P450-dependent metabolism of midazolam in hepatic microsomes from chickens, turkeys, pheasant and bobwhite quail.
Cortright KA; Craigmill AL
J Vet Pharmacol Ther; 2006 Dec; 29(6):469-76. PubMed ID: 17083450
[TBL] [Abstract][Full Text] [Related]
35. Human cytochrome P-450 3A4: in vitro drug-drug interaction patterns are substrate-dependent.
Wang RW; Newton DJ; Liu N; Atkins WM; Lu AY
Drug Metab Dispos; 2000 Mar; 28(3):360-6. PubMed ID: 10681383
[TBL] [Abstract][Full Text] [Related]
36. Role of cytochrome P450 3A4 in human metabolism of MK-639, a potent human immunodeficiency virus protease inhibitor.
Chiba M; Hensleigh M; Nishime JA; Balani SK; Lin JH
Drug Metab Dispos; 1996 Mar; 24(3):307-14. PubMed ID: 8820421
[TBL] [Abstract][Full Text] [Related]
37. Atmospheric pressure desorption/ionization on silicon ion trap mass spectrometry applied to the quantitation of midazolam in rat plasma and determination of midazolam 1'-hydroxylation kinetics in human liver microsomes.
Steenwyk RC; Hutzler JM; Sams J; Shen Z; Siuzdak G
Rapid Commun Mass Spectrom; 2006; 20(24):3717-22. PubMed ID: 17117443
[TBL] [Abstract][Full Text] [Related]
38. In vitro, pharmacokinetic, and pharmacodynamic interactions of ketoconazole and midazolam in the rat.
Kotegawa T; Laurijssens BE; Von Moltke LL; Cotreau MM; Perloff MD; Venkatakrishnan K; Warrington JS; Granda BW; Harmatz JS; Greenblatt DJ
J Pharmacol Exp Ther; 2002 Sep; 302(3):1228-37. PubMed ID: 12183684
[TBL] [Abstract][Full Text] [Related]
39. Interaction of miconazole, ketoconazole and itraconazole with rat-liver microsomes.
Lavrijsen K; van Houdt J; Thijs D; Meuldermans W; Heykants J
Xenobiotica; 1987 Jan; 17(1):45-57. PubMed ID: 3030012
[TBL] [Abstract][Full Text] [Related]
40. Comparison of two azole antifungal drugs, ketoconazole, and fluconazole, as modifiers of rat hepatic monooxygenase activity.
Houston JB; Humphrey MJ; Matthew DE; Tarbit MH
Biochem Pharmacol; 1988 Feb; 37(3):401-8. PubMed ID: 2827686
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
